The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study

Yang, Yi-Hsin; Yang, Yea-Huei Kao; Cheng, Ching-Lan; Ho, Pei-Shan; Ko, Ying-Chin

doi:10.1186/1471-2407-12-582

Table 2 Estimated odds ratios for taking selective COX-2 Inhibitors during various prior duration

From: The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study

Duration prior to index date	Colon cancer patients		Controls		Odds Ratio	95% confidence intervals	p-value
Duration prior to index date	# with at least 1 prescription	# of nonusers	# with at lease 1 prescription	# of nonusers	Odds Ratio	95% confidence intervals	p-value
all subjects aged 18-100 years old
5 years	2588	18872	9435	69896	0.51	(0.29, 0.90)	0.021
3 years	2393	25117	8293	90607	0.58	(0.39, 0.86)	0.007
1year	1264	31959	4153	121708	0.60	(0.46, 0.80)	<.001
6 months	822	35401	2619	123242	0.72	(0.56, 0.93)	0.012
3 months	533	35690	1652	124209	0.80	(0.64, 1.01)	0.056
subjects with aged 65-100 years old
5 years	2243	10145	8242	37553	0.57	(0.31, 1.07)	0.079
3 years	2073	13600	7247	49098	0.63	(0.41, 0.97)	0.035
1year	1092	19000	3630	66182	0.64	(0.48, 0.88)	0.005
6 months	706	19386	2282	67530	0.72	(0.55, 0.95)	0.021
3 months	461	19631	1450	68362	0.83	(0.65, 1.07)	0.147
subjects with aged 18-64 years old
5 years	345	8727	1193	32344	0.36	(0.08, 1.67)	0.193
3 years	320	11517	1046	41508	0.45	(0.15, 1.34)	0.152
1year	172	15959	524	55525	0.53	(0.25, 1.11)	0.090
6 months	116	16015	336	55713	0.82	(0.46, 1.48)	0.520
3 months	72	16059	201	55848	0.73	(0.43, 1.26)	0.262
male subjects
5 years	1185	11697	4175	43446	0.48	(0.19, 1.24)	0.131
3 years	1085	15145	3673	54675	0.57	(0.30, 1.08)	0.085
1year	563	20298	1799	70685	0.59	(0.38, 1.91)	0.016
6 months	366	20495	1095	71389	0.70	(0.47, 1.05)	0.087
3 months	237	20624	660	71824	0.80	(0.56, 1.13)	0.203
female subjects
5 years	1403	7175	5260	26450	0.52	(0.25, 1.08)	0.080
3 years	1308	9972	4621	35931	0.59	(0.35, 0.98)	0.042
1year	701	14661	2354	51023	0.61	(0.42, 0.89)	0.009
6 months	456	14906	1523	51854	0.73	(0.52, 1.01)	0.056
3 months	296	15066	992	52385	0.80	(0.60, 1.07)	0.136

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us